IVF stock forecast, quote, news & analysis
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need... Show more
Why INVO Fertility (IVF) Stock Is Down -44% in the Last 30 Days
Key Takeaways
- INVO Fertility (IVF) shares fell roughly 44% over the trailing 30 days, sliding from about $1.02 to $0.57.
- The decline extends a much longer downtrend: the stock is down approximately 98% over the past 52 weeks and trades near its 52-week low.
- Shares remain below both the 50-day and 200-day moving averages, with a relative strength index near 25 pointing to deeply oversold conditions.
- Persistent net losses, negative operating cash flow, and a recent increase in shares outstanding have weighed on investor sentiment.
- As a micro-cap with a market value near $2.7 million and a beta of roughly 1.4, the stock remains prone to sharp, outsized swings.
- For additional context, explore INVO Fertility's Price Targets, Earnings, and Forecast.
- Discover how automated strategies approach this and other names on the Trending AI Robots page.
INVO Fertility (IVF) Company Overview and Market Position
INVO Fertility, Inc. is a healthcare services company focused on the fertility marketplace. The business, formerly known as NAYA Biosciences, operates through two segments: fertility clinic services and its proprietary INVOcell device. The INVOcell technology enables fertilization and early embryo development to occur inside the patient's body through an intravaginal culture (IVC) procedure, positioning it as a more accessible and lower-cost alternative to traditional in-vitro fertilization.
Beyond the device, the company builds, acquires, and operates fertility clinics, including its INVO Centers, and distributes the INVOcell technology to third-party fertility providers. Investors follow the stock for its exposure to the growing assisted reproductive technology market, its acquisition-driven expansion strategy, and its stated goal of reaching cash-flow breakeven.
INVO Fertility (IVF) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, IVF declined approximately 44%, falling from a closing level near $1.02 to roughly $0.57. The move was characterized by a steady, lower-high and lower-low pattern rather than a single-day collapse, with selling pressure accelerating through the first half of October.
The quarterly trend tells a similar story. From late July through late October, the stock also fell about 44%, even after a brief, high-volume spike on August 17, when shares traded as high as $2.80 intraday before quickly giving back those gains. That failed rally marked the beginning of a renewed slide, and the stock has since trended consistently downward toward its 52-week low.
What Drove IVF Stock Price in the Last 30 Days
The recent decline reflects a combination of fundamental and technical pressures rather than a single isolated event. As a micro-cap company with a market capitalization near $2.7 million, INVO Fertility remains highly sensitive to shifts in liquidity and investor sentiment, and its beta of roughly 1.4 underscores above-average volatility.
Fundamentally, the company continues to report net losses and negative operating cash flow, while the number of shares outstanding increased sharply on a quarter-over-quarter basis, raising dilution concerns. A current ratio below 1.0 further highlights a relatively tight near-term liquidity position. On the technical side, the stock has broken below its 50-day and 200-day moving averages and reached deeply oversold territory, yet buyers have not stepped in to establish a sustained rebound.
What Drove IVF Stock Performance Over the Last Quarter
Over the quarter, the broader narrative has been one of a small-cap growth story struggling to hold investor confidence. The August spike and rapid fade illustrate how quickly speculative interest can dissipate in a thinly traded name, after which the stock resumed its downward trajectory.
The longer-term backdrop has also been shaped by the company's strategic repositioning. INVO Fertility has pivoted toward a pure-play fertility model, divesting a majority stake in its former oncology business and pursuing an acquisition-led growth strategy aimed at profitable U.S.-based clinics. While management has targeted cash-flow breakeven, ongoing losses and the need to fund clinic acquisitions have kept pressure on the share price throughout the period.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading bots. While Tickeron offers hundreds of AI-driven bots that trade thousands of tickers, only the most relevant and highest-performing strategies appear in this section. The bots differ in approach, timeframe, and performance metrics, allowing traders to explore a range of automated methods rather than a single one-size-fits-all system. For investors tracking volatile micro-cap names such as IVF, these tools offer a way to monitor momentum and pattern-based signals. Visit the Trending AI Robots page to review the current lineup.
IVF Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape the stock's direction. The company's next earnings report is scheduled for mid-November, and investors will scrutinize revenue growth, progress toward reducing losses, and any updates on the cash-flow breakeven timeline. Updates on clinic acquisitions and the pace of share dilution will also be closely watched, given their direct impact on the equity value of this small share base.
Macroeconomic and industry dynamics, including broader trends in fertility care demand and regulatory or policy developments around assisted reproductive technology, could influence sentiment. With the stock trading at a fraction of its 52-week high and in oversold territory, any stabilization in fundamentals or renewed institutional interest could matter more than usual. As always, micro-cap investing carries elevated risk, and outcomes remain uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IVF in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
IVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 39 cases where IVF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVF's RSI Oscillator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on IVF as a result. In 69 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for IVF just turned positive on November 04, 2026. Looking at past instances where IVF's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +16.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 190 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.333) is normal, around the industry mean (4.142). P/E Ratio (0.001) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices